HERZUMA is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Cephalon, Inc.. The primary component is Trastuzumab.
Product ID | 63459-303_1319744e-b28e-4f84-80f7-388bb637f5db |
NDC | 63459-303 |
Product Type | Human Prescription Drug |
Proprietary Name | HERZUMA |
Generic Name | Trastuzumab |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2019-05-16 |
Marketing Category | BLA / BLA |
Application Number | BLA761091 |
Labeler Name | Cephalon, Inc. |
Substance Name | TRASTUZUMAB |
Active Ingredient Strength | 150 mg/20mL |
Pharm Classes | HER2/neu Receptor Antagonist [EPC],HER2/Neu/cerbB2 Antagonists [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2020-03-16 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA761091 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2020-03-16 |
Ingredient | Strength |
---|---|
TRASTUZUMAB | 150 mg/20mL |
SPL SET ID: | ae71c003-883a-4cd8-ad50-e8cc9a54e971 |
Manufacturer | |
UNII |
NDC | Brand Name | Generic Name |
---|---|---|
63459-303 | HERZUMA | TRASTUZUMAB |
63459-305 | HERZUMA | TRASTUZUMAB |
50242-132 | Herceptin | Trastuzumab |
50242-134 | Herceptin | Trastuzumab |
50242-333 | Herceptin | Trastuzumab |
67457-845 | OGIVRI | trastuzumab |
67457-847 | OGIVRI | trastuzumab |
67457-991 | OGIVRI | trastuzumab |
0006-5033 | Ontruzant | trastuzumab |
0069-0305 | Trazimera-qyyp | trastuzumab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
HERZUMA 87692867 5620455 Live/Registered |
CELLTRION, INC. 2017-11-21 |
HERZUMA 79098540 4081964 Live/Registered |
CELLTRION, INC. 2011-02-18 |